US join with Sanofi to create COVID-19 Vaccine

The Trump administration is teaming up with French pharmaceutical company Sanofi to develop a vaccine for the new coronavirus disease COVID-19. The Department of Health and Human Services (HHS) said on Tuesday it would provide “expertise and reallocated funds” to support the vaccine’s development. Sanofi will partner up with the U.S. Biomedical Advanced Research and Development Authority—known as

Continue Reading

FDA approves J&J and Grifols’ blood-stopping protein spray for surgical bleeds

Johnson & Johnson’s Ethicon unit has received a 510(k) clearance from the FDA for its Vistaseal applicators, which spray a biological sealant to stem moderate bleeding during open or laparoscopic surgical procedures. The airless spray products are the first fruit of a broad partnership between the device maker. and plasma-derived medicine manufacturer Grifols, which developed the human fibrin sealant for

Continue Reading

AZ looks to focus on early-stage cancer treatments

AstraZeneca is set to prioritize the treatment of early-stage cancers under the leadership of oncology research chief José Baselga, M.D., Ph.D. Talking to The Wall Street Journal, Baselga sketched out why he thinks splitting off from the congested pursuit of late-stage cancers will benefit AstraZeneca and patients. Under Baselga, AstraZeneca’s oncology group will initially test drugs in

Continue Reading

Gilead utilizes machine learning to find new NASH drugs

Gilead has been trying to construct a deeper NASH pipeline as prospects dim for its lead candidate in the space. Phase 3 data released in February showed the candidate, selonsertib, didn’t significantly outperform placebo in treating NASH patients who developed compensated cirrhosis because of severe liver scarring. ​While another trial evaluating the drug in less sick patients has

Continue Reading

BI broadens research pact with Vanderbilt University to develop GPCR drugs for brain disorders

Boehringer Ingelheim has been working to boost its research capabilities in central nervous system (CNS) disorders, making moves over the past year aimed specifically at adding compounds to its pipeline to address Alzheimer’s disease (AD), schizophrenia and depression. Now it’s teaming up with Vanderbilt University, located in Nashville to develop novel small molecules that modulate

Continue Reading